Your Health, We Care
On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation.
On May 2, 2019, Agios Pharmaceuticals announced that the FDA had approved ivosidenib as a monotherapy for adult patients with newly diagnosed IDH1-mutated AML who are ineligible for intensive chemotherapy.
On August 25, 2021, Servier announced that the FDA had approved ivosidenib for the treatment of IDH1-mutated cholangiocarcinoma.
On May 25, 2022, Servier announced that the FDA had approved ivosidenib in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia.
On October 24, 2023, Servier announced that the U.S. Food and Drug Administration (FDA) had approved ivosidenib for the treatment of relapsed or refractory myelodysplastic syndromes (MDS) with isocitrate dehydrogenase 1 (IDH1) mutations.
Tibsovo® (ivosidenib tablets) is the first tumor metabolism-targeted therapy approved for use in com···【more】
Recommended：682025-31-12
On October 24, 2023, Servier, a leader in the oncology field dedicated to bringing tomorrow’s hope t···【more】
Recommended：802025-31-12
Tibsovo® (ivosidenib tablets) is the first tumor metabolism-targeted therapy approved for use in combination with azacitidine for the treatment of adult patients with newly diagnos···【more】
Article source：Lucius LaosRelease date：2025-12-31Recommended：68
On October 24, 2023, Servier, a leader in the oncology field dedicated to bringing tomorrow’s hope to patients, announced today that the U.S. Food and Drug Administration (FDA) has···【more】
Article source：Lucius LaosRelease date：2025-12-31Recommended：80
Is the Lao Lucius version of Ivosidenib available on the market?Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor, has shown clinical benefits in patients with acute myelo···【more】
Article source：Lucius LaosRelease date：2024-11-28Recommended：223
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
